Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594789 | 1.00 | HTR2A (0.68) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL577758 | 0.98 | HTR2A (0.67) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Bromide SCHEMBL15661932 | 0.98 | HTR2A (0.67) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL29421606 | 0.98 | HTR2A (0.67) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Carbon Dioxide SCHEMBL14861874 | 0.94 | MTNR1A (0.65) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8021697 | 0.91 | MTNR1A (0.71) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8021722 | 0.89 | MTNR1A (0.69) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL8571210 | 0.89 | MTNR1A (0.69) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3148273 | 0.89 | HTR2A (0.56) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL29032209 | 0.88 | HTR2A (0.65) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342879-A1 | VERY EFFICIENT PROCESS FOR THE PREPARATION OF AGOMELATINE | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2024-03-27 | — | — | EP | claimed |
| CN-117720424-A | Continuous flow preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117304053-A | Purification method and application of agomelatine and/or intermediate thereof | 北京海美源医药科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-114394906-A | Preparation method of agomelatine intermediate | 中孚药业股份有限公司 | 2022-04-26 | — | — | CN | claimed |
| EP-2921473-B1 | 1-CYAN-1-(7-METHOXYL-1-NAPHTYL) METHANOL ESTER COMPOUND AND PREPARATION METHOD AND USE THEREOF | JIANGXI SYNERGY PHARMACEUTICAL CO LTD (CN) | 2017-09-27 | — | — | EP | claimed |
| EP-2934502-A1 | PROCESS FOR PREPARARING N-(2-(7-METHOXY-1-NAPHTHALENYL)ETHYL) ACETAMIDE AND SOLID FORMS THEREOF | Laboratorios Lesvi S.L. (ES) | 2015-10-28 | — | — | EP | claimed |
| EP-2921473-A1 | 1-CYAN-1-(7-METHOXYL-1-NAPHTYL) METHANOL ESTER COMPOUND AND PREPARATION METHOD AND USE THEREOF | Jiangxi Synergy Pharmaceutical Co. Ltd. (CN) | 2015-09-23 | — | — | EP | claimed |
| EP-2909166-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2015-08-26 | — | — | EP | claimed |
| US-20140336380-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | RANBAXY LABORATORIES LIMITED (IN) | 2014-11-13 | — | — | US | claimed |
| EP-2785681-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | Ranbaxy Laboratories Limited (IN) | 2014-10-08 | — | — | EP | claimed |
| WO-2013054273-A9 | PROCESS FOR THE PREPARATION OF AGOMELATINE | RANBAXY LABORATORIES LIMITED (IN) | 2013-07-11 | — | — | WO | claimed |
| WO-2013080095-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | RANBAXY LABORATORIES LIMITED (IN) | 2013-06-06 | — | — | WO | claimed |
| WO-2013054273-A2 | PROCESS FOR THE PREPARATION OF AGOMELATINE | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-18 | — | — | WO | claimed |
| EP-2562151-A1 | Processes for the preparation of agomelatine and its intermediates | Dr. Reddy's Laboratories Ltd. (IN) | 2013-02-27 | — | — | EP | claimed |
| EP-2322508-B1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA CORP (CN) | 2013-01-02 | — | — | EP | claimed |
| WO-2012127483-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF N-[2-(7-METHOXY-1-NAPHTHYL) ETHYL] ACETAMIDE | SYMED LABS LIMITED (IN) | 2012-09-27 | — | — | WO | claimed |
| WO-2012093402-A1 | PROCESSES FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)ETHYL]ACETAMIDE | SYMED LABS LIMITED (IN) | 2012-07-12 | — | — | WO | claimed |
| WO-2012070025-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | CADILA PHARMACEUTICALS LTD (IN) | 2012-05-31 | — | — | WO | claimed |
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA. CORPORATION (CN) | 2011-06-02 | — | — | US | claimed |
| EP-2322508-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA Pharma. Corporation (CN) | 2011-05-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | PNMT, INMT, PTMA | HTR2A 1021/4885MTNR1A 184/4885MTNR1B 221/4885 |
| US-20140336380-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | MC5R, MC4R, COMT | HTR2A 76/4885MTNR1A 89/4885MTNR1B 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.